Table 3.

Clinicopathologic and Operative Details of Patients with Definitive Resection

Type	Nodal	Locally advanced	Chemotherapy regimen	Response	Procedure	Bile duct resection	Lymphad enectomy	Extra-organ resection	EBL	Operati ve time, min	Histology	Final stage	Vital status	OS, mo
Primary	Yes	Yes	Gemcitabine	Partial	Hepatectomy	Yes	Yes	No	2,00 0	365	Adenoca	T3N1	Dead	50.9
Primary	Yes	No	Gemcitabine + Erlotinib	Partial	Segment 4–5 Resection	No	Yes	No	300	248	Adenoca	T3N2	Dead	55.3
Primary	No	Yes	Gemcitabine + Cisplatin + MEK162	Stable	Hepatectomy	Yes	Yes	No	500	268	Adenoca	T2N0	Alive	3.8
Primary	Yes	No	Gemcitabine + Cisplatin	Stable	Segment 4–5 resection	Yes	Yes	Yes	750	337	Adenoca	T3N2	Alive	8.4
Primary	Yes	Yes	Gemcitabine + Cisplatin	Stable	Extended hepatectomy	Yes	Yes	Yes	800	386	Adenoca	T3N1	Alive	14.7
Primary	No	Yes	Gemcitabine + Cisplatin	Stable	Extended hepatectomy	Yes	Yes	No	750	356	Adenoca	T3N1	Dead	30.3
Primary	Yes	No	Gemcitabine + Cisplatin	Partial	Segment 4–5 resection	No	Yes	No	50	141	Adenoca	T3N1	Dead	19.6
Primary	Yes	No	Gemcitabine + Cisplatin	Stable	Segment 4–5 resection	Yes	Yes	No	1000	160	Adenoca	T3N0	Dead	11.7
Incidental	Yes	No	Gemcitabine + Cisplatin	Stable	Segment 4–5 resection	No	Yes	No	150	177	Adenoca	T2N1	Alive	38.7
Primary	Yes	No	Gemcitabine + Cisplatin	Partial	Segment 4–5 resection	No	Yes	No	200	178	Adenoca	T0N0	Alive	7.3

EBL, estimated blood loss, OS, overall survival.